|1.||de Haan, Judy B: 4 articles (07/2015 - 06/2009)|
|2.||Huang, Ling: 4 articles (05/2015 - 11/2013)|
|3.||Li, Xingshu: 4 articles (05/2015 - 11/2013)|
|4.||Nogueira, Cristina W: 4 articles (05/2012 - 02/2003)|
|5.||Pierce, Carol: 4 articles (04/2007 - 02/2004)|
|6.||Gu, Rende: 4 articles (04/2007 - 02/2004)|
|7.||Lynch, Eric D: 4 articles (04/2007 - 02/2004)|
|8.||Kil, Jonathan: 4 articles (04/2007 - 02/2004)|
|9.||Zeni, Gilson: 4 articles (07/2005 - 02/2002)|
|10.||Souza, Diogo O: 4 articles (11/2004 - 09/2002)|
01/01/2004 - "Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]-one), a selenoorganic compound, is effective for acute ischemic stroke; however, its effect on EC has not yet been elucidated. "
04/01/2002 - "Recently, ebselen improved the outcome of acute ischemic stroke in humans. "
01/01/1998 - "Early treatment with ebselen improved the outcome of acute ischemic stroke. "
09/01/2006 - "One of the inhibitors, ebselen, is a seleno compound used in clinical trials as a protective agent against ischemic stroke. "
08/01/2003 - "This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window. "
|2.||Wounds and Injuries (Trauma)
03/01/2006 - "Ebselen lost its high protection against 3-triol-induced injuries in the presence of GSH probably due to the formation of the ebselen-GSH adduct. "
02/01/2014 - "Therefore, ebselen may have potential to treat secondary injuries of TBI."
04/01/2010 - "Ebselen restored microcirculatory impairment within the injured muscle, as given by values of nutritive perfusion (763 +/- 44 cm/cm2), nicotinamide adenine dinucleotide levels (56 +/- 3 aU) and inflammatory cell interaction (leukocytes: 226 +/- 31 mm(-2)) at 24 hours after trauma, being not different to those found in noninjured muscle tissue of controls. "
04/01/2010 - "In an additional series of animals, ebselen or DMSO were applied without soft tissue trauma. "
03/01/2005 - "This study was aimed to investigate the possible beneficial effects of Ebselen in comparison with Methylprednisolone in experimental SCI. Thirty six Wistar albino rats (200-250 g) were divided in to six groups; A (control), B (only laminectomy), C (Trauma; laminectomy + spinal trauma), D (Placebo group; laminectomy + spinal trauma + serum physiologic), E (Methylprednisolone group; laminectomy + spinal trauma + Methylprednisolone treated), F (Ebselen group; laminectomy + spinal trauma + Ebselen treated), containing 6 rats each. "
08/01/2001 - "Prolonged neuroprotective efficacy of ebselen was determined by counting neuronal nuclei (NeuN) immunopositive cells at 21 days after ischemia. "
04/01/1995 - "The effects of Ebselen (DR-3305) upon cardiac function and CK leakage with or without ischemia reperfusion insults were investigated in this isolated working rat heart study. "
01/01/2015 - "Before sciatic nerve I/R was induced, ebselen was injected intraperitoneally at doses of 15 and 30 mg/kg. After a 2 h ischemia and a 3 h reperfusion period, sciatic nerve tissues were excised. "
01/01/2015 - "We investigated the neuroprotective role of ebselen pretreatment in rats with experimental sciatic nerve ischemia-reperfusion (I/R) injury. "
01/01/2011 - "Ebselen was administered to animals in the treatment group 2 hours prior to the induction of forebrain ischemia, and placebo was administered in the control group. "
12/01/2010 - "Our data suggest that ebselen effectively repletes the lack of GPx1, and indicate that ebselen may be an effective therapeutic for the treatment of diabetes-related atherosclerosis and nephropathy. "
06/01/2009 - "In vivo studies now investigate ebselen, a seleno-organic GPx1-mimetic, for its potential to reduce diabetes-associated atherosclerosis. "
12/01/2010 - "Ebselen reduced diabetes-associated atherosclerosis in most aortic regions, with the exception of the aortic sinus, and protected dKO mice from renal structural and functional injury. "
12/01/2010 - "To investigate the effect of the GPx1-mimetic ebselen on diabetes-associated atherosclerosis and renal injury in a model of increased oxidative stress. "
01/01/2004 - "Inhibition of JNK by ebselen may imply its usefulness for the prevention of atherosclerosis relevant to EC activation."
09/17/2014 - "In this study, the effects of ebselen (1 μM-40 μM) on AR42J tumor cells have been examined. "
09/17/2014 - "Ebselen is a seleno-organic compound that causes cell death in several cancer cell types. "
01/01/2014 - "However, experimental evidence also shows that ebselen causes cell death in several cancer cell types whose mechanism has not yet been elucidated. "
02/01/2010 - "Consequently endogenous ROS generation in DU-145 tumor spheroids was increased in the presence of either IA or 2-DDG, which was abolished upon coincubation with ebselen. "
07/30/2015 - "Daily oral treatment with ebselen resulted in a 58% reduction in tumor growth in mice bearing human pancreatic tumor xenografts compared to controls. "
|3.||Sodium Selenite (Selenite)
|4.||Ascorbic Acid (Vitamin C)
|6.||Caspase 3 (Caspase-3)
|7.||Mesna (Coenzyme M)
|9.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|1.||Transplantation (Transplant Recipients)
|2.||Induced Heart Arrest (Cardioplegia)
|3.||Intensive Care (Surgical Intensive Care)
|4.||Mechanical Ventilators (Ventilator)